Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167297 · ClinicalTrials.gov registry record · Phase 2
Atomoxetine for the Treatment of Cannabis Dependence
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00167297 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 16 participants.
The verdict
NCT00167297, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this small open-label trial is to evaluate the feasibility of recruiting cannabis dependent patients for treatment with Atomoxetine and MIT. The clinical data to date on Atomoxetine has been limited to children and adults with attention deficit disorder without co-morbid substance dependence. However, one study estimated that adults with attention deficit disorder have rates of drug abuse three to four times higher than controls (Mannuzza S 1998). The study also reported that cannabis and cocaine are most frequently abused in this population.
Interventions
- DRUG Atomoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167297
The ClinicalTrials.gov registry entry for NCT00167297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00167297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167297 about?
NCT00167297 is a clinical study titled "Atomoxetine for the Treatment of Cannabis Dependence". The purpose of this small open-label trial is to evaluate the feasibility of recruiting cannabis dependent patients for treatment with Atomoxetine and MIT. The clinical data to date on Atomoxetine has been limited to children and adults with attention deficit disorder without co-morbid substance dep...
What is the current status of trial NCT00167297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2004-11. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00167297?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00167297?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.